Protease-activated receptor signaling in platelets activates cytosolic phospholipase a2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 2, 2011, Pages 435-442

  Holinstat, Michael ^a   Boutaud, Olivier ^b   Apopa, Patrick L ^a   Vesci, Joanne ^a   Bala, Manju ^b   Oates, John A ^b   Hamm, Heidi E ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

12 lipoxygenase; aspirin; cPLA2; cyclooxygenase 1; eicosanoids; thrombosis

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; BUTANOL; CALCIUM; CYCLOOXYGENASE 1; CYTOSOLIC PHOSPHOLIPASE A2; CYTOSOLIC PHOSPHOLIPASE A2ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPRANOLOL; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; THROMBOXANE A2; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE;

1-BUTANOL; 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONIC ACID; BLOOD PLATELETS; CALCIUM; CHROMONES; CYCLOOXYGENASE 1; CYTOSOL; EICOSANOIDS; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HUMANS; MORPHOLINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROPRANOLOL; PROTEIN KINASE C; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; THROMBOXANE A2;

EID: 79551480210     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219527     Document Type: Article

References (42)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
3. Henriksen RA, Hanks VK. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol. 2002;22:861-866.
4. Kramer RM, Roberts EF, Hyslop PA, Utterback BG, Hui KY, Jakubowski JA. Differential activation of cytosolic phospholipase A2 (CPLA2) by thrombin and thrombin receptor agonist peptide in human platelets: evidence for activation of CPLA2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem. 1995;270:14816-14823.
5. 2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost. 2006;4:638-647.
6. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Teng CM. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost. 2003;90:299-308.
7. Adler DH, Cogan JD, Phillips JA III, Schnetz-Boutaud N, Milne GL, Iverson T, Stein JA, Brenner DA, Morrow JD, Boutaud O, Oates JA. Inherited human CPLA(2a) deficiency is associated with impaired eico-sanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest. 2008;118:2121-2131.
8. Herbertsson H, Kuhme T, Hammarstrom S. A 12(S)-HETE receptor in Lewis lung carcinoma cells. Adv Exp Med Biol. 1999;447:193-198.
9. Fonlupt P, Croset M, Lagarde M. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets. Thromb Res. 1991;63: 239-248.
10. Johnson EN, Brass LF, Funk CD. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Proc Natl Acad Sci USA. 1998;95:3100-3105.
11. Miller AW, Katakam PV, Lee HC, Tulbert CD, Busija DW, Weintraub NL. Arachidonic acid-induced vasodilation of rat small mesenteric arteries is lipoxygenase-dependent. J Pharmacol Exp Ther. 2003;304: 139-144.
12. Nyby MD, Sasaki M, Ideguchi Y, Wynne HE, Hori MT, Berger ME, Golub MS, Brickman AS, Tuck ML. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther. 1996;278:503-509.
13. Ozeki Y, Ito H, Nagamura Y, Unemi F, Igawa T. 12(S)-HETE plays a role as a mediator of expression of platelet CD62 (P-selectin). Platelets. 1998;9:297-302.
14. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, Nie D, Honn KV. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007;26:503-524.
15. Quintana LF, Guzman B, Collado S, Claria J, Poch E. A coding polymorphism in the 12-lipoxygenase gene is associated to essential hypertension and urinary 12(S)-HETE. Kidney Int. 2006;69:526-530.
16. Zink MH, Oltman CL, Lu T, Katakam PV, Kaduce TL, Lee H, Dell-sperger KC, Spector AA, Myers PR, Weintraub NL. 12-Lipoxygenase in porcine coronary microcirculation: implications for coronary vasoregu-lation. Am J Physiol Heart Circ Physiol. 2001;280:H693-H704.
17. Coffey MJ, Coles B, Locke M, Bermudez-Fajardo A, Williams PC, Jarvis GE, O'Donnell VB. Interactions of 12-lipoxygenase with phospholipase A2 isoforms following platelet activation through the glycoprotein VI collagen receptor. FEBS Lett. 2004;576:165-168.
18. Holinstat M, Voss B, Bilodeau ML, Hamm HE. Protease-activated receptors differentially regulate human platelet activation through a phos-phatidic acid-dependent pathway. Mol Pharmacol. 2007;71:686-694.
19. Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE. PAR4, but not PAR1, signals human platelet aggregation via CA2 + mobilization and synergistic P2Y12 receptor activation. J Biol Chem. 2006;281:26665-26674.
20. Lee SH, Williams MV, DuBois RN, Blair IA. Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom. 2003;17:2168-2176.
21. Boutaud O, Brame CJ, Salomon RG, Roberts LJ 2nd, Oates JA. Characterization of the lysyl adducts formed from prostaglandin H2 via the levuglandin pathway. Biochemistry. 1999;38:9389-9396.
22. Balsinde J, Balboa MA, Li WH, Llopis J, Dennis EA. Cellular regulation of cytosolic group iv phospholipase A2 by phosphatidylinositol bisphosphate levels. J Immunol. 2000;164:5398-5402.
23. Subramanian P, Vora M, Gentile LB, Stahelin RV, Chalfant CE. Anionic lipids activate group iva cytosolic phospholipase A2 via distinct and separate mechanisms. J Lipid Res. 2007;48:2701-2708.
24. Holinstat M, Preininger AM, Milne SB, Hudson WJ, Brown HA, Hamm HE. Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates. Mol Pharmacol. 2009;76:301-313.
25. Nemenoff RA, Winitz S, Qian NX, Van Putten V, Johnson GL, Heasley LE. Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C. J Biol Chem. 1993;268:1960-1964.
26. McNicol A, Shibou TS. Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb Res. 1998;92:19-26.
27. Gijon MA, Spencer DM, Kaiser AL, Leslie CC. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A2. J Cell Biol. 1999;145:1219-1232.
28. Kuliopulos A, Mohanlal R, Covic L. Effect of selective inhibition of the p38 map kinase pathway on platelet aggregation. Thromb Haemost. 2004;92:1387-1393.
29. Dutilh CE, Haddeman E, Jouvenaz GH, Ten Hoor F, Nugteren DH. Study of the two pathways for arachidonate oxygenation in blood platelets. Lipids. 1979;14:241-246.
30. He H, Genovese KJ, Nisbet DJ, Kogut MH. Phospholipase C, phosphatidylinositol 3-kinase, and intracellular [Ca(2+)] mediate the activation of chicken HD11 macrophage cells by CpG oligodeoxynucleotide. Dev Comp Immunol. 2008;32:1111-1118.
31. Husebye ES, Flatmark T. Phosphatidylinositol kinase of bovine adrenal chromaffin granules: modulation by hydrophilic and amphiphilic cations. Biochem Pharmacol. 1988;37:4149-4156.
32. Gerrard JM, White JG, Rao GH, Townsend D. Localization of platelet prostaglandin production in the platelet dense tubular system. Am J Pathol. 1976;83:283-298.
33. Baba A, Sakuma S, Okamoto H, Inoue T, Iwata H. Calcium induces membrane translocation of 12-lipoxygenase in rat platelets. J Biol Chem. 1989;264:15790-15795.
34. Chang WC, Nakao J, Orimo H, Murota S. Effects of reduced glutathione on the 12-lipoxygenase pathways in rat platelets. Biochem J. 1982;202: 771-776.
35. Clark JD, Schievella AR, Nalefski EA, Lin LL. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal. 1995;12:83-117.
36. Das S, Cho W. Roles of catalytic domain residues in interfacial binding and activation of group IV cytosolic phospholipase A2. J Biol Chem. 2002;277:23838-23846.
37. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the group iv phospholipase A2 family. Prog Lipid Res. 2006;45:487-510.
38. Leslie CC. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fatty Acids. 2004;70:373-376.
39. Six DA, Dennis EA. Essential Ca(2+)-independent role of the group iva cytosolic phospholipase A(2) C2 domain for interfacial activity. J Biol Chem. 2003;278:23842-23850.
40. Tucker DE, Ghosh M, Ghomashchi F, Loper R, Suram S, John BS, Girotti M, Bollinger JG, Gelb MH, Leslie CC. Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A2a in regulating interfacial kinetics and binding and cellular function. J Biol Chem. 2009;284:9596-9611.
41. Eynard AR, Galli G, Tremoli E, Maderna P, Magni F, Paoletti R. Aspirin inhibits platelet 12-hydroxy-eicosatetraenoic acid formation. J Lab Clin Med. 1986;107:73-78.
42. Siegel MI, McConnell RT, Cuatrecasas P. Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14- eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci USA. 1979;76:3774-3778.